Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;49(11):4751-3.
doi: 10.1128/AAC.49.11.4751-4753.2005.

Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis

William R Kirkpatrick  1 , Ana C Vallor, Robert K McAtee, Neil S Ryder, Annette W Fothergill, Michael G Rinaldi, Thomas F Patterson
Affiliations

Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis

William R Kirkpatrick et al. Antimicrob Agents Chemother. 2005 Nov.

Abstract

Antagonistic effects of combination therapy using amphotericin B (AmB) with agents which block ergosterol synthesis are a concern. Terbinafine was evaluated with AmB to assess antagonism or synergy in a rabbit model of invasive aspergillosis. Terbinafine had relatively little activity but did not demonstrate antagonism against AmB in our model.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Cumulative mortality of rabbits treated with terbinafine, amphotericin B, and a combination of terbinafine and amphotericin B. Rabbits (n = 8 per group) were challenged on the second day. Controls received no antifungal therapy. Treated rabbits had TRB 100 (TRB), AmB 0.4, AmB 1, or a combination of TRB 100 and AmB 0.4 initiated 24 h after challenge and were treated daily for 5 days. Mean days of survival (x.x ± standard errors) from the day of challenge with Aspergillus fumigatus are noted by group. *, P < 0.0007 versus controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Barchiesi, F., A. M. Schimizzi, F. Caselli, A. Novelli, S. Fallani, D. Giannini, D. Arzeni, S. Di Cesare, L. F. Di Francesco, M. Fortuana, A. Giacometti, F. Carle, T. Mazzei, and G. Scalise. 2000. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2435-2441. - PMC - PubMed
    1. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715. - PMC - PubMed
    1. Kirkpatrick, W. R., R. K. McAtee, A. W. Fothergillg, D. Loebenber, M. G. Rinaldi, and T. F. Patterson. 2000. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. 44:780-782. - PMC - PubMed
    1. McGinnis, M. R., and M. G. Rinaldi. 1991. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids, p. 198-251. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, Md.
    1. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.

Publication types